Sirolimus-eluting coronary stent - JW Medical Systems

Drug Profile

Sirolimus-eluting coronary stent - JW Medical Systems

Alternative Names: Excel; Excel DES; Excel-II

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator JW Medical Systems
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease
  • Phase II/III Coronary artery restenosis

Most Recent Events

  • 17 Mar 2016 EXCEL-II sirolimus-eluting coronary stent is still in phase II/III trials for Coronary artery disease (Treatment-naive) and Coronary artery restenosis (Prevention) in China
  • 15 Mar 2016 Biomarkers information updated
  • 12 Feb 2015 JW Medical systems completes enrolment in its phase II trial for Coronary artery disease (treatment naive) in China (9174729; NCT02057978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top